Ixaltis

About:

Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs.

Website: http://www.ixaltis.com/

Top Investors: IRDI, IXO Private Equity, Principia SGR, Sofimac Investment Managers, Pierre Olivier Goineau

Description:

Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs. The company was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé. The vision of IXALTIS is to develop treatments for genito-urinary tract diseases with still a high unmet medical need, by identifying drugs which had already reached clinical stage and reexplore these for use in genitourinary tract disorders. IXALTIS has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.

Total Funding Amount:

$8M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Toulouse, Midi-Pyrenees, France

Founded Date:

2012-01-01

Contact Email:

contact(AT)ixaltis.com

Founders:

Christian Chavy, Pascal Rischmann, Philippe Lluel, Roberto Gradnik, Stefano Palea, Xavier Gamé

Number of Employees:

11-50

Last Funding Date:

2016-05-31

IPO Status:

Private

Industries:

© 2025 bioDAO.ai